Citations

Clear

74 citation(s) found for "Simari, Robert".

Regulation of Circulating Progenitor Cells in Left Ventricular Dysfunction
Boilson, Barry A. , Larsen, Katarína, Harbuzariu, Adriana , Delacroix, Sinny , Kořínek, Josef , Froehlich, Harald , Bailey, Kent R. , Scott, Christopher G. , Shapiro, Brian P. , Boerrigter, Guido, Chen, Horng H. , Redfield, Margaret M. , Burnett, John C. , Simari, Robert D., Scott, Christopher

Mayo Clinic

Circulation: Heart Failure | June 24, 2010 | Volume: 3 | Issue: 5 | Pages: 635-642

10.1161/circheartfailure.109.879437 | PMID 20573992 Get It

Background— Reductions in numbers of circulating progenitor cells (CD34+ cell subsets) have been demonstrated in patients at risk for, or in the presence of, cardiovascular disease. The mediators of these reductions remain undefined. To determine whether neurohumoral factors might regulate circulating CD34+ cell subsets in vivo, we studied complementary canine models of left ventricular (LV) dysfunction. Methods and Results— A pacing model of severe LV dysfunction and a hypertensive renal wrap model in which dogs were randomized to receive deoxycorticosterone acetate (DOCA) were studied. Circulating CD34+ cell subsets including hematopoietic precursor cells (HPCs: CD34+/CD45 dim /VEGFR2−) and endothelial progenitor cells (EPCs: CD34+/CD45−/VEGFR2+) were quantified. Additionally, the effect of mineralocorticoid excess on circulating progenitor cells in normal dogs was studied. The majority of circulating CD34+ cells expressed CD45dimly and did not express VEGFR2, consistent with an HPC phenotype. HPCs were decreased in response to pacing, and this decrease correlated with plasma aldosterone levels (Spearman rank correlation=−0.67, P =0.03). In the hypertensive renal wrap model, administration of DOCA resulted in decreased HPCs. No changes were seen in EPCs in either model. Normal dogs treated with DOCA exhibited a decrease in HPCs in peripheral blood but not bone marrow associated with decreased telomerase activity. Conclusions— This is the first study to demonstrate that mineralocorticoid excess, either endogenous or exogenous, results in reduction in HPCs. These data suggest that mineralocorticoids may induce accelerated senescence of progenitor cells, leading to their reduced survival and decline in numbers.
Response to Letter Regarding Article, “Manuscript Preparation and Publication”
Holmes, David R. , Nishimura, Rick A., Simari, Robert D., Hodgson, Patricia

Mayo Clinic

Circulation | June 7, 2010 | Volume: 121 | Issue: 22 | Pages: No page available

10.1161/circulationaha.109.929125 Get It

Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis
White, Thomas A. , Johnson, Tucker F. , Zarzhevsky, Natalia, Tom, Cindy W., Delacroix, Sinny , Holroyd, Eric, Maroney, Susan A. , Singh, Ripudamanjit, Pan, Shuchong, Fay, William P. , Deursen, Jan van, Mast, Alan E. , Sandhu, Gurpreet S. , Simari, Robert D.

Mayo Clinic

Blood | June 2, 2010 | Volume: 116 | Issue: 10 | Pages: 1787-1794

10.1182/blood-2009-10-250910 | PMID 20516367 Get It

AbstractThe antithrombotic surface of endothelium is regulated in a coordinated manner. Tissue factor pathway inhibitor (TFPI) localized at the endothelial cell surface regulates the production of FXa by inhibiting the TF/VIIa complex. Systemic homozygotic deletion of the first Kunitz (K1) domain of TFPI results in intrauterine lethality in mice. Here we define the cellular sources of TFPI and their role in development, hemostasis, and thrombosis using TFPI conditional knockout mice. We used a Cre-lox strategy and generated mice with a floxed exon 4 (TFPIFlox) which encodes for the TFPI-K1 domain. Mice bred into Tie2-Cre and LysM-Cre lines to delete TFPI-K1 in endothelial (TFPITie2) and myelomonocytic (TFPILysM) cells resulted in viable and fertile offspring. Plasma TFPI activity was reduced in the TFPITie2 (71% ± 0.9%, P < .001) and TFPILysM (19% ± 0.6%, P < .001) compared with TFPIFlox littermate controls. Tail and cuticle bleeding were unaffected. However, TFPITie2 mice but not TFPILysM mice had increased ferric chloride–induced arterial thrombosis. Taken together, the data reveal distinct roles for endothelial- and myelomonocytic-derived TFPI.
Mentoring
Holmes, David R. , Hodgson, Patricia, Simari, Robert D., Nishimura, Rick A.

Mayo Clinic

Circulation | January 18, 2010 | Volume: 121 | Issue: 2 | Pages: 336-340

10.1161/circulationaha.108.798321 | PMID 20083720 Get It

Ethical Issues in Cardiovascular Research Involving Humans
Frye, Robert L. , Simari, Robert D., Brumm, Shari K., Myerle, Kathleen, Jaffe, Allan S. , Holmes, David R. , Gersh, Bernard J. , Burnett, John , Jaffe, Allan S. , Lerman, Amir , Terzic, André

Mayo Clinic

Circulation | November 23, 2009 | Volume: 120 | Issue: 21 | Pages: 2113-2121

10.1161/circulationaha.107.752766 | PMID 19933950 Get It

Manuscript Preparation and Publication
Holmes, David R. , Hodgson, Patricia, Nishimura, Rick A., Simari, Robert D.

Mayo Clinic

Circulation | September 8, 2009 | Volume: 120 | Issue: 10 | Pages: 906-913

10.1161/circulationaha.107.752782 | PMID 19738151 Get It

Vascular-Directed Tissue Factor Pathway Inhibitor Overexpression Regulates Plasma Cholesterol and Reduces Atherosclerotic Plaque Development
Pan, Shuchong, White, Thomas A. , Witt, Tyra A. , Chiriac, Anca , Mueske, Cheri S., Simari, Robert D.

Mayo Clinic

Circulation Research | August 28, 2009 | Volume: 105 | Issue: 7 | Pages: 713-720

10.1161/circresaha.109.195016 | PMID 19713537 Get It

Rationale: Tissue factor pathway inhibitor (TFPI) is a potent regulator of the tissue factor pathway and is found in plasma in association with lipoproteins. Objective: To determine the role of TFPI in the development of atherosclerosis, we bred mice which overexpress TFPI into the apolipoprotein E–deficient (apoE −/− ) background. Methods and Results: On a high-fat diet, smooth muscle 22α (SM22α)-TFPI/apoE −/− mice were shown to have less aortic plaque burden compared to apoE −/− mice. Unexpectedly, SM22α-TFPI/apoE −/− had lower plasma cholesterol levels compared to apoE −/− mice. Furthermore, SM22α-TFPI mice fed a high-fat diet had lower cholesterol levels than did wild-type mice. Because TFPI is associated with lipoproteins and its carboxyl terminus (TFPIct) has been shown to be a ligand for the very-low-density lipoprotein (VLDL) receptor, we hypothesized that TFPI overexpression may regulate lipoprotein distribution. We quantified VLDL binding and uptake in vitro in mouse aortic smooth muscle cells from SM22α-TFPI and wild-type mice. Mouse aortic smooth muscle cells from SM22α-TFPI mice demonstrated higher VLDL binding and internalization compared to those from wild-type mice. Because SM22α-TFPI mice have increased circulating levels of TFPI antigen, we examined whether TFPIct may act to alter lipoprotein distribution. In vitro, TFPIct increased VLDL binding, uptake, and degradation in murine embryonic fibroblasts. Furthermore, this effect was blocked by heparinase treatment. In vivo, systemic administration of TFPIct reduced plasma cholesterol levels in apoE −/− mice. Conclusions: These studies suggest that overexpression of TFPI lowers plasma cholesterol through the interaction of its carboxyl terminus with lipoproteins and heparan sulfate proteoglycans.
Tissue Factor Pathway Inhibitor Overexpression Inhibits Hypoxia-Induced Pulmonary Hypertension
White, Thomas A. , Witt, Tyra A. , Pan, Shuchong, Mueske, Cheryl S., Kleppe, Laurel S., Holroyd, Eric, Champion, Hunter C., Simari, Robert D.

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | July 31, 2009 | Volume: 43 | Issue: 1 | Pages: 35-45

10.1165/rcmb.2009-0144oc | PMID 19648471 Get It

Abstract Pulmonary hypertension (PH) is a commonly recognized complication of chronic respiratory disease. Enhanced vasoconstriction, pulmonary vascular remodeling, and in situ thrombosis contribute to the increased pulmonary vascular resistance observed in PH associated with hypoxic lung disease. The tissue factor pathway regulates fibrin deposition in response to acute and chronic vascular injury. We hypothesized that inhibition of the tissue factor pathway would result in attenuation of pathophysiologic parameters typically associated with hypoxia-induced PH. We tested this hypothesis using a chronic hypoxia–induced murine model of PH using mice that overexpress tissue factor pathway inhibitor (TFPI) via the smooth muscle–specific promoter SM22 (TFPISM22). TFPISM22 mice have increased pulmonary TFPI expression compared with wild-type (WT) mice. In WT mice, exposure to chronic hypoxia (28 d at 10% O2) resulted in increased systolic right ventricular and mean pulmonary arterial pressures, changes that were significantly reduced in TFPISM22 mice. Chronic hypoxia also resulted in significant pulmonary vascular muscularization in WT mice, which was significantly reduced in TFPISM22 mice. Given the pleiotropic effects of TFPI, autocrine and paracrine mechanisms for these hemodynamic effects were considered. TFPISM22 mice had less pulmonary fibrin deposition than WT mice at 3 days after exposure to hypoxia, which is consistent with the antithrombotic effects of TFPI. Additionally, TFPISM22 mice had a significant reduction in the number of proliferating (proliferating cell nuclear antigen positive) pulmonary vascular smooth muscle cells compared with WT mice, which is consistent with in vitro findings. These findings demonstrate that overexpression of TFPI results in improved hemodynamic performance and reduced pulmonary vascular remodeling in a murine model of hypoxia-induced PH. This improvement is in part due to the autocrine and paracrine effects of TFPI overexpression.
Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide
Pan, Shuchong, Chen, Horng H. , Dickey, Deborah M., Boerrigter, Guido, Lee, Candace, Kleppe, Laurel S., Redfield, Margaret M. , Potter, Lincoln R. , Burnett, John C. , Simari, Robert D., Lee, Candace Y.W., Hall, Jennifer L. , Lerman, Amir

Mayo Clinic

Proceedings of the National Academy of Sciences | June 18, 2009 | Volume: 106 | Issue: 27 | Pages: 11282-11287

10.1073/pnas.0811851106 | PMID 19541613 Get It

Alternative RNA splicing may provide unique opportunities to identify drug targets and therapeutics. We identified an alternative spliced transcript for B-type natriuretic peptide (BNP) resulting from intronic retention. This transcript is present in failing human hearts and is reduced following mechanical unloading. The intron-retained transcript would generate a unique 34 amino acid (aa) carboxyl terminus while maintaining the remaining structure of native BNP. We generated antisera to this carboxyl terminus and identified immunoreactivity in failing human heart tissue. The alternatively spliced peptide (ASBNP) was synthesized and unlike BNP, failed to stimulate cGMP in vascular cells or vasorelax preconstricted arterial rings. This suggests that ASBNP may lack the dose-limiting effects of recombinant BNP. Given structural considerations, a carboxyl-terminal truncated form of ASBNP was generated (ASBNP.1) and was determined to retain the ability of BNP to stimulate cGMP in canine glomerular isolates and cultured human mesangial cells but lacked similar effects in vascular cells. In a canine-pacing model of heart failure, systemic infusion of ASBNP.1 did not alter mean arterial pressure but increased the glomerular filtration rate (GFR), suppressed plasma renin and angiotensin, while inducing natriuresis and diuresis. Consistent with its distinct in vivo effects, the activity of ASBNP.1 may not be explained through binding and activation of NPR-A or NPR-B. Thus, the biodesigner peptide ASBNP.1 enhances GFR associated with heart failure while lacking the vasoactive properties of BNP. These findings demonstrate that peptides with unique properties may be designed based on products of alternatively splicing.
Carotid Repair Using Autologous Adipose-Derived Endothelial Cells
Froehlich, Harald , Gulati, Rajiv , Boilson, Barry A. , Witt, Tyra A. , Harbuzariu, Adriana , Kleppe, Laurel S., Dietz, Allan B. , Simari, Robert D., Lerman, Amir , Dietz, Allan B

Mayo Clinic

Stroke | March 13, 2009 | Volume: 40 | Issue: 5 | Pages: 1886-1891

10.1161/strokeaha.108.539932 | PMID 19286583 Get It

Background and Purpose— Adipose tissue is an abundant source of endothelial cells as well as stem and progenitor cells which can develop an endothelial phenotype. It has been demonstrated that these cells have distinct angiogenic properties in vitro and in vivo. However, whether these cells have the capacity to directly improve large vessel form and function after vascular injury remains unknown. To define whether delivery of adipose-derived endothelial cells (ADECs) would improve healing of injured carotid arteries, a rabbit model of acute arterial injury was used. Methods— Autologous rabbit ADECs were generated using defined culture conditions. To test the ability of ADECs to enhance carotid artery repair, cells were delivered intraarterially after acute balloon injury. Additional delivery studies were performed after functional selection of cells before delivery. Results— After rabbit omental fat harvest and digestion, a proliferative, homogenous, and distinctly endothelial population of ADECs was identified. Direct delivery of autologous ADECs resulted in marked reendothelialization 48 hours after acute vascular injury as compared to saline controls (82.2±26.9% versus 4.2±3.0% P <0.001). Delivery of ADECs that were selected for their ability to take up acetylated LDL significantly improved vasoreactivity and decreased intimal formation after vascular injury. Conclusions— Taken together, these data suggest that ADECs represent an autologous source of proliferative endothelial cells, which demonstrate the capacity to rapidly improve reendothelialization, improve vascular reactivity, and decrease intimal formation in a carotid artery injury model.